RenovoRx, Inc.
For the period ended Dec 31, 2025. Filed Mar 30, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 30, 2026
RNXT$1.180.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Convertible Preferred Stock and Stockholders’ Equity
(in thousands, except share amounts)
| ConvertiblePreferred Stock · Common Stock · AdditionalPaid-In · Accumulated · TotalStockholders'Equity | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount · Shares · Amount · Capital · Deficit · (Deficit) | ||||||||||||
| Balance—December 31, 2024 | - | $ | - | 24,034,672 | $ | 2 | $ | 54,695 | $ | (50,219) | $ | 4,478 |
| Issuance of common stock upon equity financing, net of issuance cost | - | - | 11,523,810 | 2 | 10,801 | - | 10,803 | |||||
| Issuance of common stock upon exercise of pre-funded common warrants | - | - | 951,500 | - | - | - | - | |||||
| Issuance of common stock upon exercise of common warrants | - | - | 25,252 | - | 25 | - | 25 | |||||
| Issuance of common stock upon exercise of stock options | - | - | 39,650 | - | 17 | - | 17 | |||||
| Issuance of restricted stock awards, net | - | - | 39,032 | - | - | - | - | |||||
| Stock-based compensation expense | - | - | - | - | 1,267 | - | 1,267 | |||||
| Net loss | - | - | - | - | - | (11,168) | (11,168) | |||||
| Balance—December 31, 2025 | - | - | 36,613,916 | $ | 4 | $ | 66,805 | $ | (61,387) | $ | 5,422 | |
| Balance—December 31, 2023 | - | $ | - | 10,693,580 | $ | 1 | $ | 38,404 | $ | (41,405) | $ | (3,000) |
| Issuance of common stock upon exercise of stock options | - | - | 93,481 | - | 69 | - | 69 | |||||
| Issuance of common stock upon the private placement offering | - | - | 13,094,278 | 1 | 15,015 | - | 15,016 | |||||
| Issuance of common stock upon exercise of common warrants | - | - | 33,333 | - | 33 | - | 33 | |||||
| Issuance of restricted stock awards | - | - | 120,000 | - | - | - | - | |||||
| Stock-based compensation expense | - | - | - | - | 1,174 | - | 1,174 | |||||
| Net loss | - | - | - | - | - | (8,814) | (8,814) | |||||
| Balance—December 31, 2024 | - | - | 24,034,672 | $ | 2 | $ | 54,695 | $ | (50,219) | $ | 4,478 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.